Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol in Prostate Cancer Patients Undergoing Prostatectomy
NCT03152786Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of propranolol in prostate cancer (PCa) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Mean Level of CREB Phosphorylation at 2 hours. Started Jan 2019; status: terminated.
02
Drugs
propranolol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03152786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152786.